Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 5/20 | 0.43 |
| ▸ | BRAF | P15056 | 5/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.35 |
| ▸ | TCF7L2 | Q9NQB0 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718829 | 0.96 | RAF1 (0.43) | RAF1BRAFCTNNB1TCF7L2MAPT | |
| Trifluoroacetic Acid SCHEMBL2719359 | 0.93 | RAF1 (0.46) | RAF1BRAFSYKSLC2A1TP53 | |
| Trifluoroacetic Acid SCHEMBL2720769 | 0.93 | RAF1 (0.46) | RAF1BRAFMAPTSYKSLC2A1 | |
| SCHEMBL2718524 | 0.91 | RAF1 (0.39) | RAF1BRAFCTNNB1TCF7L2MAPT | |
| SCHEMBL14346039 | 0.91 | RAF1 (0.42) | RAF1BRAFCTNNB1TCF7L2MAPT | |
| Trifluoroacetic Acid SCHEMBL2720026 | 0.90 | RAF1 (0.46) | RAF1BRAFMAPK14SYKKDR | |
| Trifluoroacetic Acid SCHEMBL2721213 | 0.90 | RAF1 (0.37) | RAF1BRAFMAPK14MAPK13MAPK12 | |
| Trifluoroacetic Acid SCHEMBL2718569 | 0.89 | RAF1 (0.43) | RAF1BRAFSYKSLC2A1 | |
| SCHEMBL3531127 | 0.89 | RAF1 (0.46) | RAF1BRAFMAPK14MAPK13MAPK12 | |
| SCHEMBL3526785 | 0.89 | RAF1 (0.46) | RAF1BRAFMAPTMAPK14SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354416-B2 | 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl]-5-fluoro-4-methyl-N-(1-methylethyl)benzamide; treating CSBP/p38 kinase mediated diseases; cytokine suppressive anti-inflammatory drugs; mitogen-activated protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2013-01-15 | — | — | US | disclosed |
| US-8207176-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| EP-2447266-A1 | Pyrimidopyridine compound used as a CSBP/RK/p38 modulator | GLAXO GROUP LIMITED (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20100144755-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| US-7678801-B2 | 3-(8-(2,6-Difluorophenyl)-2-{[2-(methylamino)ethyl]amino}-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl)-4-methyl-N-1,3-thiazol-2-ylbenzamide; treating CSBP/p38 kinase mediated diseases; cytokine suppressive anti-inflammatory drugs; mitogen-activated protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2010-03-16 | — | — | US | disclosed |
| US-20090156597-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-06-18 | — | — | US | disclosed |
| US-20090069318-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| US-20060235029-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144755-A1 | Novel Compounds | MAPKAPK2, CDC42BPB, MAPK8 | RAF1 206/4885BRAF 100/4885CTNNB1 1350/4885 |
| US-20090156597-A1 | Novel Compounds | MAPKAPK2, MAPK8, MAPKAPK3 | RAF1 163/4885BRAF 84/4885CTNNB1 1087/4885 |
| US-20060235029-A1 | Novel compounds | MAPKAPK2, CDC42BPB, MAPK8 | RAF1 206/4885BRAF 100/4885CTNNB1 1350/4885 |
| US-20090069318-A1 | Novel Compounds | MAPKAPK2, MAPK8, MAPKAPK3 | RAF1 163/4885BRAF 84/4885CTNNB1 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.